A federal judge in Delaware put a patent infringement spat between C.R. Bard subsidiary SenoRx and Hologic (NSDQ:HOLX) on hold for 90 days last week.
SenoRx Inc.
Hologic wins patent fight on appeal
C.R. Bard absorbs SenoRx
C.R. Bard Inc. (NYSE:BCR) closed its acquisition of SenoRx Inc. (NSDQ:SENO).
The Murray Hill, N.J.-based device conglomerate bought Irvine, Calif.-based SenoRx for about $200 million, or $11 per share.